Anna Nijdam Sells 1,829 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 1,829 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.60, for a total transaction of $55,967.40. Following the completion of the transaction, the insider owned 48,945 shares in the company, valued at approximately $1,497,717. This trade represents a 3.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total transaction of $169,100.74.

Pharvaris Stock Performance

Shares of PHVS opened at $29.47 on Thursday. Pharvaris N.V. has a 52 week low of $15.46 and a 52 week high of $33.33. The firm has a market cap of $1.93 billion, a P/E ratio of -9.27 and a beta of -2.34. The firm’s 50-day simple moving average is $28.66 and its 200 day simple moving average is $27.01.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current year.

Institutional Trading of Pharvaris

A number of institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its holdings in Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Pharvaris during the 4th quarter worth approximately $35,000. Public Employees Retirement System of Ohio lifted its holdings in shares of Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after acquiring an additional 1,300 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the period.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Short interest in Pharvaris fell sharply in mid-May, dropping 42.9% to 600,645 shares. That lower bearish positioning can be viewed as a constructive signal for the stock.
• Positive Sentiment: Brokerage coverage remains supportive, with Pharvaris receiving a consensus rating of “Moderate Buy,” which suggests analysts still see meaningful upside potential. Article link
• Neutral Sentiment: The company also continues to trade near the upper end of its 52-week range after beating first-quarter EPS estimates, which helps reinforce investor confidence in the name. Article link
• Negative Sentiment: Recent insider selling by CFO David Nassif, Director Viviane Monges, and insider Anna Nijdam may be pressuring sentiment, even though some of the sales were tied to tax withholding or equity vesting. Article link

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. Wedbush boosted their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Royal Bank Of Canada cut their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. UBS Group set a $74.00 price objective on shares of Pharvaris in a report on Wednesday, May 13th. Finally, Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.